• 1.

    Rodriguez E, et al.. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017; 10:320322. doi: 10.1093/ckj/sfx024

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Skoczynska M, et al.. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus 2020; 29:631639. doi: 10.1177/0961203320917460

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Nakamura H, et al.. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: A case report successfully treated with eculizumab. Nephron 2018; 138:324327. doi: 10.1159/000485194

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Palomo M, et al.. Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 2019; 14:17191732. doi: 10.2215/CJN.05830519

  • 5.

    Ariceta G, et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int [published online ahead of print December 8, 2020]. doi: 10.1016/j.kint.2020.10.046; https://www.kidney-international.org/article/S0085-2538(20)31418-6/fulltext

    • Search Google Scholar
    • Export Citation
  • 6.

    Jayne DRW, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:27562767. doi: 10.1681/ASN.2016111179

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Jayne DRW, et al.. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599609. doi: 10.1056/NEJMoa2023386

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Merkel PA, et al.. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc 2020; 9:e16664. doi: 10.2196/16664

    • Search Google Scholar
    • Export Citation

Complement Inhibition in Kidney Disease. What’s on the Horizon?

  • 1 Maria Jose Soler, MD, PhD, FERA, is a nephrologist, and Natalia Ramos, MD, PhD, is a nephrology attendant with the Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain.
Restricted access
Save